Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Thoughts After Amylyx AMX0035 Committee: How Special Is ALS At FDA?

Executive Summary

An advisory committee rejection of the proposed ALS therapy AMX0035 amounts to a vote in favor of US FDA’s approach to the review. It also amounts to an implicit rejection of the idea that ALS merits unique approaches given the devastating nature of the illness.

You may also be interested in...



House User Fee Mark-Up: Few Tweaks, But Concerns About ALS And Accelerated Approval

Clinical trial diversity, FDA hiring authority, and inactive ingredient disclosure provisions all get slight modifications. The bill glides through committee, but not without some complaints about agency performance.

Amylyx’s ALS Drug Should Wait For Phase III Results, US FDA Panel Says

Six of 10 advisory committee members say Phase II CENTAUR trial cannot stand on its own to support approval at this time. However, patients and advocates say thousands will die if they have to wait for the Phase III PHOENIX trial to complete in 2024 before the drug becomes widely available.

Amylyx’s ALS Drug Brings Questions On Efficacy Data Robustness To US FDA Panel

Citing numerous concerns about design of the Phase II CENTAUR trial and statistical robustness of the results, agency reviewers question whether a single study provides substantial evidence of efficacy for approval of AMX0035.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145969

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel